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Abstract 
Purpose: The PI3K/AKT/P70S6K pathway is an attractive therapeutic target in ovarian 
and uterine malignancies due to its high rate of dysregulation and key roles in tumor 
growth. Here, we examined the biological effects of MSC2363318A, which is a novel 
inhibitor of AKT1, AKT3, and P70S6K. 
Experimental Design: Orthotopic murine models of ovarian and uterine cancer were 
utilized to study the effect of MSC2363318A on survival and regression. Moreover, in 
vitro experiments (MTT, Western blot analysis, plasmid transfection, and reverse phase 
protein array [RPPA]) were carried out to characterize underlying mechanisms and 
potential biomarkers of response.   
Results: MSC2363318A decreased tumor growth and metastases in multiple murine 
orthotopic models of ovarian (SKOV3ip1, HeyA8, and Igrov1) and uterine (Hec1a) 
cancer and reduced proliferation (Ki67) and angiogenesis (CD31) indices and 
increased cell death (cleaved caspase-3) markers. Synergy between MSC2363318A 
and paclitaxel was observed in vitro in protected (IC50 ≥ 5 µM) cell lines. RPPA 
identified YAP1 as a candidate marker to predict cell lines that were most sensitive to 
MSC2363318A (R=0.675, p=0.0015). After establishment of a bevacizumab resistant 
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endothelial cell line, RF-24, we demonstrate that resensitization to bevacizumab occurs 
with the addition of MSC2363318A. 
Conclusions: MSC2363318A has therapeutic efficacy in multiple pre-clinical models of 
ovarian and uterine cancer. These findings support clinical development of dual 
AKT/P70S6K inhibition. 
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1 
Introduction 
Epidemiology and standard of care for ovarian and uterine malignancy 
Ovarian cancer remains the seventh most common malignancy worldwide and 
represents approximately 4% of new cancer cases diagnosed each year in women [1]. 
It is the eighth most common cause of cancer deaths.  The estimated five year overall 
survival of newly diagnosed ovarian cancer depends on the stage of disease at 
diagnosis.  Epithelial carcinoma is the most common histologic type of ovarian cancer 
and accounts for 90% of cases. The histologic subtypes include high grade serous, 
which accounts for 70-80% of cases, endometrioid, clear cell, mucinous, and low grade 
serous [2,3]. Due to a lack of effective screening, vague symptomology, and advanced 
disease presentation, patients with advanced stage IIIC and stage IV disease have an 
overall survival of 32.5 and 18.6%, respectively [4].    
In developed countries, uterine cancer is the most common malignancy and the 
second most common worldwide [1].  The majority of women (68%) are diagnosed at 
an earlier stage when disease is confined to the uterus [5].  This is primarily due to 
symptoms of postmenopausal bleeding. Adenocarcinoma of the uterus is the most 
common histologic subtype of uterine cancer and is broadly classified into type 1 or 
type 2 tumors, which differ in their incidence, responsiveness to estrogen, and clinical 
behavior [6,7].  Type 1 tumors are low grade (grade 1 or 2), endometrioid histology, 
and comprise the majority of adenocarcinomas (approximately 80%).  These are 
primarily estrogen dependent and have a favorable prognosis.  In contrast, type 2 
tumors consist of high grade endometrioid histology (grade 3) and non-endometrioid 
histologies, including serous, clear cell, squamous, undifferentiated, mucinous and 
 
 
2 
transitional cell types.  These tumors are not estrogen dependent and have a more 
aggressive clinical course.  
Staging for both diseases can be classified generally to the location of the 
primary disease at diagnosis and the presence of distant metastases.  Generally 
speaking, in stage 1 disease, tumor growth is limited to the primary disease site (either 
the ovary or uterus).  In stage 2 disease, tumor has spread to other disease sites within 
the pelvis for ovary or to the vagina in uterine cancer.  In stage 3 disease, tumor has 
spread intra-abdominally outside of the pelvis and/or to the retroperitoneal lymph nodes 
(Figure 1).  Stage 4 comprises distant metastases including parenchymal liver 
involvement or malignant pleural effusions [8].  
Figure 1.  Laparoscopic assessment of disease burden involving the bilateral 
ovaries and peritoneum.  Photo courtesy of Alpa Nick, M.D. 
 
Cytroreductive surgery to no gross residual disease and comprehensive surgical 
staging followed by adjuvant taxane- and platinum based chemotherapy regimens 
 
 
3 
remain the mainstay of upfront treatment [9] for ovarian cancer.  Despite the 
effectiveness of frontline treatment, the majority (62%) of women will recur and 
ultimately die of their disease.  In women with stage III or IV disease, 80-85% will recur.  
Second-line chemotherapy or surgery in selected cases is offered to women with 
recurrent disease.  More recently, anti-angiogenic therapies [10,11], PARP inhibitors in 
women with a BRCA mutation [12,13], and genomic testing of the tumor [14,15] have 
been employed to improve progression free and overall survival. Bevacizumab and 
olaparib were the first two biologic therapies approved for ovarian cancer. 
The administration of bevacizumab as a frontline agent in women with newly 
diagnosed ovarian cancer has been evaluated by two randomized controlled studies:  
GOG218 and ICON7.  In GOG218, women were randomized to receive: (1) standard 
chemotherapy with carboplatin and paclitaxel; (2) bevacizumab plus standard 
chemotherapy for six cycles followed by placebo until month 15, or (3) bevacizumab 
plus standard chemotherapy followed by bevacizumab until month 15.  There was a 
significant increase in progression free survival of patients that received bevacizumab 
plus chemotherapy followed by bevacizumab, but there was no improvement of overall 
survival [16].  ICON7 randomized women newly diagnosed with ovarian cancer to 
standard carboplatin or paclitaxel for six cycles with or without bevacizumab during 
chemotherapy and then as a maintenance treatment for 12 additional cycles.  While 
there was a significant improvement in progression free survival in the women who 
received bevacizumab (24 versus 22 months), there was no difference in overall 
survival [17].   
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The use of bevacizumab in the setting of relapsed disease has also been 
evaluated.  In GOG17D, women (n=62) with platinum-resistant disease were treated 
with bevacizumab, and two patients had complete responses and 11 had partial 
responses.  Median progression free survival and overall survival were 4.7 and 17 
months, respectively [10].  In another Phase II study, women with platinum-resistant 
ovarian cancer received single agent bevacizumab and median progression free 
survival was 4.4 months.  Median survival duration was 10.7 months [18]. 
In December 2014, the Food and Drug Administration granted accelerated 
approval for olaparib as a treatment for women with BRCA1 or BRCA2 mutations 
following three or more lines of previous chemotherapy.  This approval came from 
Study 19, which evaluated women with BRCA-associated platinum-sensitive ovarian 
cancer.  This trial included nearly 300 women with recurrent disease who were 
randomized to receive treatment with olaparib or placebo.  There was a significant 
improvement in progression free survival (eight versus five months) in the women who 
were treated with olaparib [12].  An interim analysis did not show an overall survival 
benefit.  A separate analysis of patients with a known BRCA mutation suggested that 
the clinical benefit was the highest in this subset of patients, with a significant 
improvement in progression free survival (11 versus 4 months) and a trend toward an 
improvement in overall survival [13].    
Hysterectomy, bilateral salpingo-oophorectomy, with pelvic or para-aortic lymph 
node dissection (or sentinel lymph node assessment) is the recommended staging 
procedure for patients with uterine cancer [19]. In women that present with pelvic or 
intra-abdominal disease, complete cytoreduction has been associated with prolonged 
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overall survival [20].  Adjuvant treatment of women following surgery depends on their 
individual risk of recurrence and the presence of persistent disease. Women are 
stratified into low-, intermediate-, and high-intermediate, and high risk for recurrence 
and may receive combination taxane- and platinum based chemotherapy with or 
without radiation.   
The estimated five year survival of newly diagnosed ovarian and uterine cancer 
patients can be broken down by FIGO stage. Most ovarian cancers are of epithelial 
origin and present with high grade and late stage; the five year overall survival is 
dismal, around 30%.  Early stage disease uterine cancer portends a five year overall 
survival of 90%, but higher stage disease has five year overall survivals that are similar 
to that of ovary (Tables 1-2). 
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Table 1.  Five year overall survival in ovarian cancer patients by stage at 
diagnosis [8]. 
FIGO stage 5-year Overall Survival (%) 
IA 89.6 
IB 86.1 
IC 83.4 
IIA 70.7 
IIB 65.5 
IIC 71.4 
IIIA 46.7 
IIIB 41.5 
IIIC 32.5 
IV 18.6 
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Table 2.  Five year overall survival in uterine cancer patients by stage at 
diagnosis [19]. 
FIGO stage 5-year Overall Survival (%) 
IA 90 
IB 78 
II 74 
IIIA 56 
IIIB 36 
IIIC1 57 
IIIC2 49 
IVA 22 
IVB 21 
 
The Cancer Genome Atlas (TCGA) provides an important resource for 
understanding the molecular pathogenesis of these malignancies. Using 489 high 
grade serous ovarian cancer samples, TCGA analysis showed the high prevalence of 
TP53 mutations in almost all of the samples (96%). Other recurrent somatic mutations 
were found in NF1, BRCA1, BRCA2, RB1, and CDK12 genes [21].  Further analysis, 
found that homologous recombination is frequently abnormal in about half of the cases, 
with NOTCH and FOXM1 cell signaling also altered [21].  From the uterine cancer 
TCGA analysis, uterine serous tumors had frequent TP53 mutations, extensive copy 
number alterations, and low levels of estrogen and progesterone receptors.  In the 
endometrioid tumors that were examined, there were much fewer copy number 
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alterations and mutations in TP53, but there were frequent mutations in PTEN, 
CTNNB1, PIK3CA, ARID1A, KRAS, and ARID5B. A subset of endometrioid tumors had 
increased transversion mutation frequency in POLE [22]. 
In women with recurrent, refractory disease, new therapeutic agents are needed 
to impact survival and potentially cure women of metastases. Multiple classes of 
targeted therapies have been developed to target the tumor cells in these solid 
malignancies and the cells within the tumor microenvironment.  Within the 
microenvironment, targeting the vasculature with anti-vascular endothelial growth factor 
(VEGF) therapy with a commonly used monoclonal antibody, bevacizumab, has shown 
to induce partial responses and/or stable disease [10].  Bevacizumab binds VEGF, 
preventing it from binding to VEGF receptors.  Because of the poor prognosis of 
ovarian and type 2 endometrial cancers with little improvement in the outcomes of 
women with standard surgery and adjuvant chemotherapy, a better understanding of 
the complex interplay of the tumor microenvironment with aberrant tumor cell signaling 
is warranted. 
 
The PI3K/AKT/mTOR pathway and malignancy 
The PI3K/AKT/mTOR pathway controls important cellular processes necessary 
for tumorigenesis and metastasis including survival, proliferation, metabolism, 
regulation of cell cycle, angiogenesis, and genomic instability (Figure 2) [23]. This 
pathway plays a pivotal role in many malignant features involved in tumor pathogenesis 
and is intimately linked with most of the hallmarks of cancer [24]. Genomic studies 
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suggest that aberrations within this signaling pathway are among the most frequently 
altered in malignancies. 
Figure 2.  Overview of the PI3K/AKT/mTOR pathway. 
 
PI3K is a major downstream effector of G-coupled protein receptors and tyrosine 
kinase receptors. Three classes of PI3K have been recognized:  (1) Class IA PI3K 
includes IA PIK3α, β, and δ, all of which are activated by receptors that have receptor 
tyrosine kinase activity; (2) Class IB PI3K includes PI3Kγ, which are subsequently 
activated by G-coupled protein receptors.  The Class IA PI3Ks are heterodimers and 
consist of p110 catalytic and p85 regulatory subunits.  The three genes, PIK3CA, 
PIK3CB, and PIK3CD, encode the three classes of 1A p110 isoforms (α, β, and δ).  Of 
these three genes, only PIK3CA is mutated frequently in human malignancies [23].   
Activated PI3K phosphorylates phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2; 
PIP2) to generate phosphatidylinositol (3,4,5)-triphosphate (PI(3,4,5)P3; PIP3). AKT is 
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recruited to the cell’s plasma membrane where it can be phosphorylated at its 
serine473 or threonine308 residues. The tumor suppressor, PTEN, and INPP4B are 
responsible for the negative regulation of activation. PTEN dephosphorylates PIP3 at 
the 3-position phosphate of PIP3, which produces PIP2.  INPP4B is responsible for the 
dephosphorylation of phosphatidylinositol (3,4)-bisphosphate (PI(3,4)P2) to form PI(3)P 
at the 4-position phosphate group [25]. Constitutive activation of AKT results from the 
loss of either PTEN or INPP4B, which them leads to the accumulation of PIP3 or 
PI(3,4)P2, respectively.  Phosphorylated or activated AKT phosphorylates mTOR at the 
serine2448 residue, which activates mTORC1.  Indirectly, AKT can also active 
mTORC1 through phosphorylation of the tuberous sclerosis complex (TSC2).  
Phosphorylated TSC2 leads to the inactivation of the functional TSC1/TSC2 complex.  
However, when this complex is activated, TSC2 enables the conversion of Rheb-GTP 
(Ras homolog enriched in brain-GTP) to Ras-GDP, which then inactivates mTORC1.  
Once TSC2 is phosphorylated or inactivated by AKT, Rheb-GTP is responsible for 
stimulating the activity of mTORC1.  The other complex, mTORC2, is activated through 
an unclear mechanism, but PI3K may be responsible for its activation [26].  Once 
activated, mTORC2 phosphorylates other kinases, such as AKT, kinases present in the 
serum and glucocorticoid, and kinases that regulate lipogenesis, the metabolism of 
glucose, influence apoptosis, and are involved in the cellular cytoskeleton. 
Once phosphorylated, mTORC1 phosphorylates ribosomal S6 kinase-1, which 
regulates protein translation and 4EBP-1, the eukaryotic translation initiation factor.  
S6K-1 activation then leads to downstream translation of mRNA encoding ribosomal 
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proteins, factors responsible for elongation, and proteins responsible for cell cycle 
progression [27]. 
 
PI3K/AKT pathway alterations in ovarian and uterine cancer 
Genetic and/or epigenetic changes lead to activation of the PI3K/AKT signaling 
pathway in multiple cancers.  Ovarian, type 1, and type 2 uterine cancers exhibit 
alterations in this pathway [21,28]. Additionally, previous analyses have found this 
pathway to be activated in half of high grade serous ovarian carcinomas. The PIK3CA 
gene, which encodes the catalytic isoform p100α, is a commonly mutated oncogene, 
affecting over 30% of solid tumors [29].  PTEN, which encodes phosphatase and tensin 
homolog, is one of the most frequently mutated tumor suppressor genes and is 
frequently suppressed or downregulated leading to activation of the PI3K/AKT signaling 
pathway [30]. Frequent aberrations of this pathway in ovarian cancer include mutations 
in PTEN [31] or hypermethylation of the promoter [32], loss of heterozygosity at the 
INPP4B locus [25], somatic mutations in mTOR and AKT1 [33], amplification of AKT2 
[34], somatic activating mutations in the PIK3CA gene [35], and activating mutations in 
the PIK3R1 gene [36].  
Uterine cancers harbor the highest rates of PI3K/AKT pathway alterations 
[37].  PTEN mutations, often occur early in uterine cancer pathogenesis, are frequently 
identified in type 1 tumors, and have been identified in 34-55% of endometrial cancers 
[22]. Other frequently identified pathway mutations in uterine cancer include PIK3CA 
(25-40%), PIK3R1 (15-25%), and less commonly, AKT1-3 mutations (2-5%) 
[38,39,40,41]. 
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The tumor microenvironment and the PI3K/AKT pathway 
 Almost all cells within the tumor microenvironment are influenced by the 
PI3K/AKT signaling pathway. Tumor cells secrete pro-angiogenic factors including 
VEGF that activate quiescent endothelial cells.  New vasculature originates from 
existing blood vessels from proliferation and activated endothelial cells through vessel 
co-option [42]. Additionally, cells derived from the bone marrow including monocytes, 
endothelial progenitor cells, and mast cells also promote the new growth and 
maintenance of blood vessels [43].  The PI3Ks have been established as controls of 
hypoxia-inducible factor (HIF)-1α expression and VEGF secretion [44,45,46].  Within 
the endothelial cells, the PI3Ks are responsible for the transduction of signals that are 
downstream of angiogenic receptors.  These include receptors in the VEGF family such 
as VEGFR-1/Flt-1, VEGFR-2/Flk-1, and VEGFR3 [47,48,49]. Upon phosphorylation of 
AKT, downstream effects are activated including migration of endothelial cells, 
proliferation, and tubulogenesis. Additionally, other endothelial cell stimuli and ligands 
have been shown to activate the endothelial cell including angiopoietin-1, insulin, 
insulin-like growth factor-1, hepatocyte growth factor, estrogen, fluid shear stress, 
reactive oxygen species, and corticosteroids [50,51,52,53,54,55,56,57].  The activation 
of AKT by VEGF within endothelial cells requires matrix attachment and promotes 
endothelial cell viability [58]. 
Targeting the cell microenvironment, specifically the PI3K/AKT pathway, within 
endothelial cells, may provide a rational approach to overcoming resistance to anti-
angiogenic therapy in the clinical setting.   
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The high prevalence of these molecular alterations in ovarian and uterine 
cancers, combined with the druggability of the PI3K/AKT pathway in the tumor cells 
and the microenvironment, represents an important therapeutic opportunity. 
 
Hypothesis and specific aims: 
 
Hypothesis:  Dual inhibition of AKT and P70S6K will reduce tumor growth by 
decreasing angiogenesis, inhibiting tumor cell proliferation, and promoting 
apoptosis in ovarian and uterine cancer cells. 
• Specific Aim 1:  To determine the prevalence of PI3K/AKT/P70S6 
alterations in ovarian and uterine cancer. 
• Specific Aim 2: To assess the efficacy of an AKT/P70S6 inhibitor 
(MSC2363318A) in combination with chemotherapeutic agents (taxanes 
and bevacizumab) in vitro and in vivo using well-established mouse 
models of ovarian carcinoma.  
• Specific Aim 3: To determine the mechanisms underlying the biological 
responses to MSC2363318A-based therapy.  
 
 
 
 
 
 
 
 
14 
Materials and Methods 
 
Cell line maintenance and siRNA transfections 
All cell lines were maintained in 5% CO2 at 37 °C. Ovarian cancer (A2780, ES2, 
HeyA8, Igrov1, Ovcar3, Ovcar4, Ovcar5, Ovcar8, Ovca432, and SKOV3ip1), uterine 
cancer (AN3CA, Hec1A, Hec1B, Hec265, Ishikawa, KLE, RL95-2, Spec2 SKUT2, 
RL95-2 and KLE), and endothelial (RF-24) cells were obtained from the American Type 
Culture Collection.   A2780, ES2, HeyA8, Igrov1, Ovcar3, Ovcar4, Ovcar8, Ovca432, 
SKOV3ip1, and Hec265 were maintained in RPMI 1640 supplemented with 10–15% 
fetal bovine serum (FBS) and 0.1% gentamicin sulfate (GeminiBioproducts, Calabasas, 
CA). Endometrial cell lines were maintained and propagated in MEM (Ishikawa), 
McCoy's 5A (Hec1A), and 1:1 D-MEM:F12 (KLE and RL95-2) media supplemented 
with 10% fetal bovine serum and 0.1% gentamicin sulfate.  Spec2 was maintained in a 
1:1 mixture of DMEM and Ham's F-12 medium supplemented with 10% fetal bovine 
serum, L-glutamine, sodium pyruvate, nonessential amino acids, and a 2-fold vitamin 
solution (Life Technologies Laboratories). Ovcar5 and SKUT2 cells were maintained in 
D-MEM with 10% and 20% FBS, respectively.  Hec1b cells were maintained in MEM 
supplement supplemented with 10% FBS, glutamine, sodium pyruvate and amino 
acids. RF-24 cells were maintained in D-MEM supplemented with pyruvate, amino 
acids, and penicillin/streptomycin.  
Cell lines were obtained within one year of the work described, and per 
institutional policy (MD Anderson policy ACA#1044) cell line authentication was 
performed at least once per year. In this case, authentication was performed within six 
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months of the work described. Authentication was performed by the short tandem 
repeat method using the Promega Power Plex 16HS kit (Promega). Somatic mutations 
were detected using a Sequenom MALDI TOF MassArray system (Sequenom). 
Mycoplasma detection was performed using the MycoAlert Kit (Lonza), and all in 
vitro experiments were conducted with 60-80% confluent cultures. 
 
In vivo models 
Female athymic nude mice were purchased from Taconic Farms (Hudson, NY) 
as previously described [59]. The mice were housed and cared for according to 
guidelines set forth by the United State Public Health Service policy on Human Care 
and Use of Laboratory Animals and the American Association for Accreditation of 
Laboratory Animal Care. The University of Texas MD Anderson Cancer Center 
Institutional Animal Care and Use Committee approved and supervised all studies. All 
animals were 8–12 weeks old at the time of injection. 
Prior to injection of cells for animal experiments, cells were harvested using 
trypsin-EDTA, FBS-containing media was added, then cells were washed and 
resuspended in Hanks’ balanced salt solution (HBSS; Gibco, Carlsbad, CA) before 
injection. For the Igrov1 (1 × 106 cells in 200 μl of HBSS), SKOV3ip1 (1 × 106 cells in 
200 μl of HBSS) and HeyA8 (250 x 103 in 200 μl of HBSS) model, cells were injected 
intraperitoneally  For the uterine cancer model, Hec1A cells were injected into the right 
uterine horn (4 × 106 cells in 100 μl of HBSS ). For the intra-uterine injections, mice 
were anaesthetized with ketamine and administered buprenorphine (0.1 mg/kg) 
subcutaneously. An incision in the midline was made and using blunt dissection the 
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right uterine horn identified.  A 30-gauge needle on a 1-ml tuberculin syringe was used 
to inject the cell suspension directly into the uterus. After injection, the incision was 
closed in two layers with 0-0 Vicryl and surgical clips, and the mouse was returned to a 
cage until fully recovered. 
For all experiments, mice were treated by oral gavage daily (25 
mg/kg).  MSC2363318A was reconstituted in 0.5% Hydroxypropyl Methylcellulose 
(Hypromellose 2208, Spectrum Chemical), 0.25% Tween 20 in 100 mM Citrate buffer 
pH3 (Teknova).  For the SKOV3ip1, Hec1A, HeyA8, and Igrov1 models, treatments 
began seven to days after cell injection and continued for approximately four to six 
weeks. Mice were treated with paclitaxel (4 mg/kg) once weekly via intraperitoneal 
injection and bevacizumab (6.25 mg/kg) twice weekly via intraperitoneal 
injection.  Once mice in any group became moribund, all mice were sacrificed and 
necropsied. Tumors were harvested, and weight, number and location of metastatic 
nodules were recorded. Tumor tissue was preserved and fixed in formalin for paraffin 
embedding, frozen in optimal cutting temperature media to prepare frozen slides, or 
snap-frozen for lysate preparation. 
 
Immunoblotting 
Lysates were prepared using modified RIPA buffer (50 mM Tris–HCl (pH 7.4), 
150 mM NaCl, 1% Triton, 0.5% deoxycholate) plus 25 μg ml−1 leupeptin, 
10 μg ml−1 aprotinin, 2 mM EDTA and 1 mM sodium orthovandate. A BCA Protein Assay 
Reagent kit (Pierce Biotechnology, Rockford, IL) was used to determine the protein 
concentrations. Lysates were loaded and then separated on SDS–PAGE. Transfer of 
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protein was achieved through use of a nitrocellulose membrane by wet electrophoresis 
(Bio-Rad Laboratories, Hercules, CA) overnight, blocked with 5% BSA for one hour and 
then incubated at 4°C overnight with primary antibody (p-ribosomal S6 protein 1:1,000, 
pAKT 1:1000, AKT 1:1000, YAP1 (1:1000); p-p70S6k 1:500, p-70S6k 1:500) (Cell 
signaling, Danvers, MA)). After washing thrice with tris-buffered saline with Tween 20, 
membranes were incubated with horseradish peroxidase-conjugated horse anti-Mouse 
or Rabbit IgG (1:2,000, GE Healthcare, UK) for one hour. Visualization of horseradish 
peroxidase was performed using an enhanced chemiluminescence detection kit (Pierce 
Biotechnology). The blots were probed with an antibody specific for β-actin (0.1 μg/mL; 
Sigma) to confirm equal loading. 
 
Quantitative real-time PCR 
Total RNA was isolated using the Qiagen RNeasy kit (Qiagen, CA) and 
quantified. Complementary DNA was synthesized using 1,000 ng of RNA and a Verso 
cDNA kit (Thermo Scientific, PA), as per the manufacturer’s instructions. A 7500 Fast 
Real-Time PCR System (Applied Biosystems, CA) with SYBR green-based real-time 
PCR was used for analysis of mRNA levels for all genes.  Specific primers for YAP1 
were F-CAAGAAAGCAGGCTCACAGAA, R-GCTGGGTGTTAGGGCTTCG; and 18S 
F-CGCCGCTAGAGGTGAAATTC, R-TTGGCAAATGCTTTCGCTC were used; 18S 
was used as a housekeeping gene. PCR was done with reverse-transcribed RNA and 
100 ng/μL of sense and antisense primers in a total volume of 20 μL. Each cycle 
consisted of 15 seconds of denaturation at 95°C and 1 minute of annealing and 
extension at 60°C (40 cycles). 
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Cell viability assay 
Cell viability assays were performed by testing cell's ability to reduce the 
tetrazolium salt [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt] to a formazan. Cells were seeded in a 96-well 
plate and treated for 96 hours with increasing concentrations of MSC2363318A and 
paclitaxel and 72 hours with increasing concentrations of bevacizumab.  After 96 hours, 
cells were incubated with 0.15% 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) for 2 hours at 37°C. The supernatant was removed, cells were 
dissolved in 100-μL DMSO, and the absorbance at 540 nm was recorded. 
  
Immunohistochemistry 
Paraffin-embedded tissues were used to detect cell proliferation (with Ki67) and 
apoptosis (with cleaved caspase-3). Sections were deparaffinized sequentially in 
xylene and declining grades of ethanol prior to rehydration and transferred to PBS. 
After antigen retrieval with citrate buffer (pH 6.0), the sections were blocked with 3% 
hydrogen peroxide in methanol and protein blocker at room temperature. The sections 
were then incubated with the Ki-67 (1:200; DakoCytomation) and monoclonal mouse 
antibody against cleaved caspase-3 (1:200; Biocare Medical, Concord, CA) overnight 
at 4°C. After being washed with PBS, sections were incubated with horseradish 
peroxidase-conjugated rat anti-mouse immunoglobulin G2a (1:100; Serotec, Harlan 
Bioproducts for Science, Madison, WI) for Ki67 staining for 1 hour. 
CD31 staining was performed on frozen sections. Sections were fixed in cold 
acetone for 15 min, washed with PBS, blocked with protein blocker (4% fish gel), and 
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then incubated with rat monoclonal anti-mouse CD31 (1:800, PharMingen, San Diego, 
CA) overnight at 4°C. After washing the slides with PBS, we added the appropriate 
horseradish peroxidase–conjugated secondary antibody in blocking solution for one 
hour at room temperature. Slides were developed with 3, 3”-diaminobenzidine 
chromogen (Invitrogen, Carlsbad, CA) and counterstained with Gil’s No. 3 hematoxylin 
(Sigma-Aldrich). 
For quantification of CD31, Ki67, and cleaved caspase-3 expression, five 
samples from each group were examined. To quantify microvessel density for each 
sample, the microvessels within five randomly selected 0.159-mm2 fields at x200 were 
counted. A single microvessel was defined as a single cell or a discrete cluster of cells 
stained positive for CD31. To quantify Ki67 expression and cleaved caspase 3, the 
percentage of positive cells was determined in five random fields at x200 magnification. 
  
In vitro apoptosis assay 
For this assay, 150,000 cells were in each well of a six well plate, targeting 
approximately 50% confluence in serum-containing medium. After daily treatment with 
IC50 doses of MSC2363318A, cell viability was assessed via flow cytometry using 
Annexin V and 7-amino-actinomycin-D staining (BD Pharmingen, Franklin Lakes, NJ). 
Cells were harvested, washed, incubated for 20 minutes with PE-Annexin V and 7-
amino-actinomycin-D according to the manufacturer’s instructions, and then subjected 
to flow cytometry.  
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In vitro proliferation assay 
Cells were plated in six well plates with 150,000 cells per well, targeting 
approximately 50% confluence in serum-containing medium. Cells were treated daily 
with MSC2363318A using IC50 and IC20 doses.  The percentage of proliferating cells 
(defined as the percentage of cells in S-phase) were determined using the Click-iT EdU 
flow cytometry kit (Invitrogen). Cells were incubated with 10 mM 5-ethynyl-2-
deoxyuridine for 2 hours, lifted, and washed with 1% bovine serum albumin in 
Dulbecco’s PBS. The cells were fixed with 4% paraformaldehyde in Dulbecco’s PBS for 
15 minutes at room temperature and then maintained for a duration not exceeding 7 
days at 4oC in the dark until use. On the day flow cytometric analysis was to be 
performed, the cells were washed in 1% bovine serum albumin in PBS and 
permeabilized with 1x saponin-based reagent for 15 minutes at room temperature. 
Using a solution containing 1x reaction buffer, CuSO4, Alexa-Fluor 488 azide dye, and 
proprietary reaction buffer additive, the cells were incubated for 30 minutes at room 
temperature and then subjected to flow cytometric analysis. 
  
Development of resistant RF-24 clone 
A bevacizumab-resistant cell line was derived from original parental RF-24 cell 
line by exposing cells continuously to bevacizumab at (1 mg/mL) for 72 hours. After 72 
hours, media was removed and the cells were allowed to recover for seven days. Cells 
were maintained continuously in the presence of bevacizumab at IC50 concentrations.  
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Development of YAP1 overexpressing clone 
For ectopic expression of YAP1, we obtained a lentiviral plasmid corresponding 
to a validated full-length wild-type YAP1 from Addgene (PLX304-YAP1-V5, ID: 42555). 
We transduced Ovca432, Igrov1, and Hec1b cells with virus particles (PLX304-YAP1 
and PLX304 empty plasmid control) and then selection using neomycin/G418 
(InvivoGen; 600mg/ml) was carried out to establish stable cell variants. 
 
RF-24 tube formation assay 
Sensitive and resistant RF-24 cells were seeded at a density of 100,000 per well 
in a six well plate and allowed to attach overnight. The culture medium was then 
aspirated and replaced with fresh culture medium containing 0.5 mg/mL and cell lines 
specific IC50 doses of MSC2363318A. A 96-well plate was coated with 50 µL of 
Matrigel, which was allowed to solidify at 37°C for ten minutes. Next, 20,000 cells per 
well were seeded on the Matrigel.  The cells were incubated at 37°C for six hours. To 
assess tube formation, we counted and photographed complete tubes from randomly 
chosen fields using an Olympus inverted microscope connected to a digital camera. 
  
Statistical Analysis 
Continuous variables were compared with the two-sample t test (between two 
groups) or with analysis of variance (ANOVA; for all groups) if normally distributed (as 
determined by the Kolmogrov-Smirnov test), and the Mann-Whitney test was used if 
distributions were nonparametric. A p-value of less than 0.05 from a two-tailed 
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statistical test was considered statistically significant. All statistical tests were two-
sided. 
  
Reverse Phase Protein Arrays (RPPA) 
Igrov1, Ovcar5, Hec1B, Ishikawa ,RL95-2 KLE, RF-24 cells sensitive to 
bevacizumab, and RF-24 cells resistant to bevacizumab were treated with 1 µM 
MSC2363318A for 24 hours and subjected to RPPA as previously described 
[60,61,62]. Cellular proteins were denatured by 1% SDS (with beta-mercaptoethanol) 
and diluted in five 2-fold serial dilutions in dilution buffer (lysis buffer containing 1% 
SDS). The serial diluted lysates were then arrayed on nitrocellulose-coated slides 
(Grace Biolab) by Aushon 2470 Arrayer (Aushon BioSystems). Total 5808 array spots 
were arranged on each slide, which included the spots corresponding to positive and 
negative controls prepared from mixed cell lysates or dilution buffer, respectively. 
Each slide was probed with a validated primary antibody plus a biotin-
conjugated secondary antibody. Only antibodies with a Pearson correlation coefficient 
between RPPA and western blotting of greater than 0.7 were used in reverse phase 
protein array study. Antibodies with a single or dominant band on western blotting were 
further assessed by direct comparison to RPPA using cell lines with differential protein 
expression or modulated with ligands/inhibitors or siRNA for phospho- or structural 
proteins, respectively. 
The signal obtained was amplified using a Dako Cytomation–catalyzed system 
(Dako) and visualized by DAB colorimetric reaction. The slides were scanned, 
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analyzed, and quantified using a customerized-software Microvigene (VigeneTech Inc.) 
to generate spot intensity. 
Each dilution curve was fitted with a logistic model (“Supercurve Fitting” 
developed by the Department of Bioinformatics and Computational Biology in MD 
Anderson Cancer Center, “http://bioinformatics.mdanderson.org/OOMPA”). This fits a 
single curve using all the samples (i.e., dilution series) on a slide with the signal 
intensity as the response variable and the dilution steps are independent variable. The 
fitted curve is plotted with the signal intensities – both observed and fitted - on the y-
axis and the log2-concentration of proteins on the x-axis for diagnostic purposes. The 
protein concentrations of each set of slides were then normalized by median polish, 
which was corrected across samples by the linear expression values using the median 
expression levels of all antibody experiments to calculate a loading correction factor for 
each sample. 
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Results 
 
PI3K/AKT pathway alterations in ovarian and uterine cancer 
 To determine the prevalence of PI3K/AKT pathway alterations in ovarian and 
uterine cancer, TCGA was queried.  An oncoprint was developed for high grade serous 
ovarian cancers to incorporate the genes, AKT1, AKT2, AKT3, PTEN, RPS6KB2, and 
PIK3CA (Figure 3). The majority of alterations included amplifications of AKT1, AKT2, 
AKT3, and PIK3CA.   
 
Figure 3.  PI3K/AKT pathway has genes altered in 47% (n=272) of high grade 
serous ovarian cancer cases from The Cancer Genome Atlas.   
 
 
 A similar analysis was performed from TCGA for uterine cancer, and an 
oncoprint was developed with the same genes:  AKT1; AKT2; AKT3; PTEN; RPS6KB2; 
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and PIK3CA (Figure 4). Mutations in PTEN and PIK3CA were the dominant mutations 
identified. 
 
Figure 4.  PI3K/AKT pathway has genes altered in 90% (n=216) of uterine cases 
from The Cancer Genome Atlas. 
 
 
 
Therapeutic efficacy of MSC2363318A in orthotopic models ovarian and uterine 
cancer 
First, we carried out a dose-finding experiment with MSC2363318A in an ovarian 
model (Igrov1), whereby mice were treated with varying concentrations of drug after 
tumors were established. Downstream markers were evaluated after 12, 24, and 48 
hours of the last dose administration (Figure 5). A reduction in expression of 
downstream p-ribosomal S6 protein and resultant increase in pAKT473 (from feedback 
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loops) was observed at doses of 20 and 40 mg/kg after 24 hours.  Abrogation of this 
downstream inhibition was seen 48 hours after the last dose was administered.  
 
Figure 5.  Dose finding experiments with MSC2363318A in an ovarian orthotopic 
model. Western blot analysis of downstream markers from tumors of mice inoculated 
with Igrov1 cells and treated with vehicle, 10 mg/kg MSC2363318A, 20 mg/kg, and 40 
mg/kg after 12, 24, and 48 hours after last treatment.  
 
 
Therefore, daily administration of 25 mg/kg was chosen given the return of downstream 
markers after 24 hours and the maximum tolerated dose was between 20 and 25 
mg/kg alone and in combination with paclitaxel (Figure 6).  
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Figure 6.  Maximum tolerated dose experiment with MSC2363318A monotherapy 
and in combination with paclitaxel on non-tumor bearing mice. Body weight 
percentage differences from maximum tolerated dose experiment of non-tumor bearing 
mice after daily treatment for 14 days with MSC2363318A 20, 25, and 30 mg/kg and 20 
and 25 mg/kg combined with paclitaxel (4 mg/kg). 
 
 
Next, we carried out a series of experiments to characterize the therapeutic 
efficacy of MSC2363318A on tumor growth alone and in combination with paclitaxel, a 
commonly used frontline adjuvant therapy in gynecologic malignancies. In the 
SKOV3ip1 model, treatment with MSC2363318A monotherapy resulted in a 92.8% 
reduction in tumor weight compared to control (p<0.01) and treatment in the 
combination group with MSC2363318A paclitaxel resulted 94% reduction in tumor 
weight (p<0.05) (Figure 7A). Less distant metastases were observed at necropsy in 
monotherapy and combination therapy groups (Figure 7B-C) and reductions in tumor 
nodules were observed in all treatment groups (Figure 7D). There was 16-17% 
decrease in mouse body weight, which was not associated with any noticeable 
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changes in mobility or feeding habits (Figure 7E). A reduction in downstream p-
ribosomal S6 protein was seen in both groups treated with MSC2363318A (Figure 6F).  
 
Figure 7. Effects of MSC2363318A on ovarian tumor growth. Mice were inoculated 
with (A-C) SKOV3ip1 cells intraperitoneally and received vehicle (control), 
MSC2363318A (25 mg/kg oral daily), paclitaxel (4 mg/kg intraperitoneally weekly), or a 
combination of MSC2363318A and paclitaxel.  Tumor growth and metastatic locations 
are shown. (D) Mouse weights, (E) number of metastatic nodules, and (F) western blot 
analysis of downstream markers from tumors of mice inoculated with SKOV3ip1. Error 
bars represent the standard error of the mean (SEM). *, P < 0,05; **, P < 0.01; and ***, 
P < 0.001.  
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An additional ovarian orthotopic model with Igrov1 was performed (Figure 8A-C) 
with similar results in tumor growth and metastatic spread.  Mice treated with 
MSC2363318A had decreased weight, and combination MSC2363318A and paclitaxel 
treated mice had the fewest metastatic nodules (p<0.05) (Figure 8D-E). 
 
Figure 8.  Effects of MSC2363318A on ovarian tumor growth in a second 
orthotopic model. Mice inoculated with (A-C) Igrov1 cells received vehicle (control), 
MSC2363318A (25 mg/kg oral daily), paclitaxel (4 mg/kg intraperitoneally weekly), or a 
combination of MSC2363318A and paclitaxel beginning ten days after inoculation. The 
sites of metastases were recorded and representative pictures are shown. (D) Mouse 
weights and (E) the number of metastatic nodules were recorded at necropsy.  Error 
bars represent the standard error of the mean (SEM). *, P < 0,05; **, P < 0.01; and ***, 
P < 0.001.  
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Given the high prevalence of PI3K/AKT pathway activation, we also examined 
the biological effects of MSC2363318A in a uterine cancer model. Specifically, ten days 
following inoculation of Hec1a cells into the uterine horn, treatment with MSC2363318A 
and paclitaxel was initiated. Tumor weight was reduced in all treatment groups, but 
most significantly in the combination MSC2363318A and paclitaxel treatment group 
(85.3% reduction, p<0.0001) (Figure 9A). Local spread to the mesentery and within the 
pelvis and distant liver metastases were observed in all groups (Figure 9B-C).The most 
significant reduction in distant metastatic sites occurred in combination treatment 
groups (p=0.0003) (Figure 9D)  There was a reduction in mouse weights in the groups 
treated with monotherapy or combination MSC2363318A and paclitaxel (Figure 9E).  A 
reduction in downstream p-ribosomal S6 protein was seen in both groups treated with 
MSC2363318A (Figure 9F).  
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Figure 9.  Effects of MSC2363318A on uterine tumor growth. Mice were inoculated 
with (A-C) Hec1a cells via intrauterine horn injection and received vehicle (control), 
MSC2363318A (25 mg/kg oral daily), paclitaxel (4 mg/kg intraperitoneally weekly), or a 
combination of MSC2363318A and paclitaxel.  Tumor growth and metastatic locations 
are shown. (D) Number of metastatic nodules, (E) mouse weights, and (F) western blot 
analysis of downstream markers from tumors of mice inoculated with SKOV3ip1. Error 
bars represent the SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001; and ****, P < 0.0001. 
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Biological effects of MSC2363318A on proliferation, and apoptosis 
Given the robust therapeutic effects of MSC2363318A in vivo, we evaluated 
potential biological effects in tumors collected at necropsy. In the SKOV3ip1 model, 
treatment with combination MSC2363318A and paclitaxel resulted in the furthest 
reduction of cellular proliferation as determined by Ki67 (83% reduction, p<0.0001) 
(Figure 10A). Treatment with MSC2363318A alone or in combination with paclitaxel 
increased cleaved caspase-3 by more than 62% (p<0.0001) (Figure 10B).  
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Figure 10. Effect of MSC2363318A on proliferation and apoptosis on ovarian 
tumors.  SKOV3ip1 tumors were collected at the conclusion of in vivo therapeutic 
experiments and immunohistochemical stains were performed to evaluated the effects 
of MSC23633318A, paclitaxel, or combination therapy on cancer cell (A) proliferation 
(Ki67) and (B) apoptosis (cleaved caspase-3 [CC3])  staining. Representative sections 
(final magnification, ×20) are shown for the four treatment groups. The mean Ki67-
positive cells and mean cleaved caspase-3 cells are shown in the adjoining 
graphs.  Five fields per slide and at least five slides per treatment group were examined 
and compared using the Student t-test. Error bars represent the SEM. *, P < 0,05; **, P 
< 0.01; ***, P < 0.001, ****, P < 0.0001. 
 
 
Statistically significant reductions in CD31 (p<0.05) and Ki67 (p<0.0001) with 
increases in cleaved caspase-3 (p<0.001) occurred in the combination MSC2363318A 
and paclitaxel treated mice inoculated with Igrov1 cells (Figure 11). 
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Figure 11.  Effect of MSC2363318A on apoptosis, proliferation, and angiogenesis 
on ovarian tumors.  Igrov1 tumors were collected at the conclusion of in 
vivo therapeutic experiments and immunohistochemical stains were performed to 
evaluated the effects of MSC23633318A, paclitaxel, or combination therapy on cancer 
cell (A) cancer cell angiogenesis (CD31), (B) proliferation (Ki67), and (C) apoptosis 
(cleaved caspase-3 [CC3])  staining. Representative sections (final magnification, ×20) 
are shown for the four treatment groups. The mean Ki67-positive cells, mean cleaved 
caspase-3 cells, and average number of CD31-positive vessels per field are shown in 
the adjoining graphs.  Five fields per slide and at least five slides per treatment group 
were examined and compared using the Student t-test. Error bars represent the SEM. 
*, P < 0,05; ***, P < 0.001, ****, P < 0.0001. 
 
In the Hec1a model, all treatment groups had a statistically significant reduction 
in Ki67, but this effect was most pronounced in the combination MSC2363318A and 
paclitaxel group (52.8%, p<0.0001) (Figure 12A).  Treatment with MSC2363318A alone 
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or in combination with paclitaxel led to a 33-45% increase in cleaved caspase-3 
(p<0.01) (Figure 12B). 
 
Figure 12.  Effect of MSC2363318A on proliferation and apoptosis on uterine 
tumors.  Hec1a tumors were collected at the conclusion of in vivo therapeutic 
experiments and immunohistochemical stains were performed to evaluated the effects 
of MSC23633318A, paclitaxel, or combination therapy on cancer cell (A) proliferation 
(Ki67) and (B) apoptosis (cleaved caspase-3 [CC3])  staining. Representative sections 
(final magnification, ×20) are shown for the four treatment groups. The mean Ki67-
positive cells and mean cleaved caspase-3 cells are shown in the adjoining 
graphs.  Five fields per slide and at least five slides per treatment group were examined 
and compared using the Student t-test. Error bars represent the SEM. **, P < 0.01; and 
****, P < 0.0001. 
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In vitro effect of MSC2363318A in ovarian and uterine cancer cells lines 
Cell lines were characterized by mutation status, and we hypothesized that 
those mutations leading to activation of the PI3K/AKT pathway (such as PTEN 
inactivating mutations and PIK3CA mutations) would be the most sensitive to 
MSC2363318A inhibition (Table 3). 
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Table 3.  Mutation status of ovarian and uterine cancer cell lines [63]. 
 
The effect of MSC2363318A on a panel of ten ovarian cancer cell lines was 
tested and the median inhibitor concentration (IC50) ranged from 0.7 to 12.9 µM 
(Figure 13).  Ovca432 was identified as the most sensitive (IC50 of 0.7 µM) and 
SKOV3ip1 was the most resistant (IC50 was 12.9 µM).   
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Figure 13.  Effects of MSC2363318A on ovarian cancer cell lines.  Cell viability after 
treatment with MSC2363318A between 0 to 50 µM for 96 hours and mean inhibitory 
concentration (IC50) after treatment with MSC2363318A in ovarian cancer cell lines. 
Error bars represent the standard error of the mean (SEM). 
 
 
 
The viability of a panel of nine uterine cancer cell lines were evaluated after 
treatment with MSC2363318A and the IC50 ranged from 0.0004 to 33.8 µM (Figure 
14).  AN3CA and KLE were identified as the most sensitive and resistant cell lines, 
respectively.   
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Figure 14.  Effects of MSC2363318A on uterine cancer cell lines.  Cell viability after 
treatment with MSC2363318A between 0 to 50 µM for 96 hours and mean inhibitory  
 
concentration (IC50) after treatment with MSC2363318A in uterine cancer cell lines. 
Error bars represent the SEM.  
Due to the inhibition of tumor growth and proliferation, we tested these effects in 
vitro using resistant (defined as IC50 ≥ 5 µM) ovarian and uterine cancer cell lines, 
SKOV3ip1 and Ishikawa.  We observed significantly decreased proliferation in both cell 
lines when treated daily at the previously calculated concentrations that inhibited 20% 
of cell growth (IC20) and IC50 doses (Figure 15).  
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Figure 15. Effects of MSC2363318A on resistant ovarian and uterine cancer cell 
line proliferation. Percentage of EdU incorporation in SKOV3ip1 and Ishikawa cells 
treated daily with control (PBS) and MSC2363318A at cell line specific IC20 and IC50 
concentrations measured after 72 hours. Error bars represent the standard error of the 
mean (SEM). *, P < 0,05; and **, P < 0.01. 
 
This was also validated in sensitive ovarian and uterine cancer cell lines, Igrov1 
and Hec1b, respectively, at both concentrations (Figure 16).      
 
Figure 16. Effects of MSC2363318A on sensitive ovarian and uterine cancer cell 
line proliferation. Percentage of EdU incorporation in Igrov1 and Hec1b cells treated 
daily with control (PBS) and MSC2363318A at cell line specific IC20 and IC50 
concentrations measured after 72 hours. Error bars represent the SEM. **, P < 0.01. 
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Next, we examined the molecular signaling events involved in the PI3K/AKT 
pathway after treatment with varying concentrations of MSC2363318A.  The expression 
level of downstream target, p-ribosomal S6 protein, was reduced after treatment in 
SKOV3ip1 (Figure 17) at concentrations above 100 nM.   
 
Figure 17. Effect of MSC2363318A concentration on downstream markers in the 
PI3K/AKT pathway.  Western blot analysis of downstream and pathway markers after 
treatment of SKOV3ip1 cells with 0, 0.01, 0.1, 0.5, 1, 5, and 10 µM concentrations of 
MSC2363318A after 24 hours.  
 
 
 
This duration of this effect was between 1 and 24 hours after treatment of SKOV3ip1 
cells with 1 µM MSC2363318A (Figure 18).  
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Figure 18.  Effect of time on MSC2363318A on downstream markers in the 
PI3K/AKT pathway. Western blot analysis of downstream markers after treatment of 
SKOV3ip1 cells treated with 1 µM MSC2363318A for times specified.  
 
 
 
Paclitaxel, a commonly used chemotherapeutic used in the frontline and 
recurrent setting in ovarian and uterine cancer, was tested in combination with 
MSC2363318A and contributed to the most profound inhibition of tumor growth and 
metastases in vivo, so the effect of combination treatment was tested in vitro.  MTT 
analysis demonstrated a dose-dependent decrease in cell viability after combination 
therapy with paclitaxel and IC20 and IC50 concentrations of MSC2363118A.  The 
combination index (CI) was obtained after performing an Isobologram analysis, which 
showed synergistic cytotoxicity in Ishikawa and SKOV3ip1 cells between these two 
treatments (Figure 19A-B).   
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Figure 19. In vitro effects of MSC2363318A and paclitaxel in resistant ovarian and 
uterine cancer cell lines. (A) SKOV3ip1 and (B) Ishikawa were treated with different 
concentrations of paclitaxel alone or in combination with the cell line specific IC20 or 
IC50 for 96 hours followed by MTT analysis to determine percent cell viability.  Error 
bars represent the SEM. The combination index (CI) was calculated after performing 
isobologram analysis. A CI of < 1.0 indicates synergism, a CI of 1 indicates additive 
activity and a CI > 1.0 indicates antagonism. 
 
The only other cell line, which showed similar synergy of paclitaxel and 
MSC2363318A, was in the treatment of uterine cancer cell line, SKUT2 (Figure 20A). 
Sensitive ovarian and uterine cancer cell lines, Igrov1 and Hec1b, suggested an 
additive effect when treated concurrently with paclitaxel and MSC2363318A at IC20 
and IC50 doses (Figure 20B-C).   
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Figure 20. In vitro effects of MSC2363318A and paclitaxel in sensitive ovarian and 
uterine cancer cell lines.  (A) SKUT2, (B) Igrov1, and (C) Hec1b were treated with 
different concentrations of paclitaxel alone or in combination with the cell line specific 
IC20 or IC50 for 96 hours followed by MTT analysis to determine percent cell 
viability.  The combination index (CI) was calculated after performing isobologram 
analysis for SKUT2. A CI of < 1.0 indicates synergism, a CI of 1 indicates additive 
activity and a CI > 1.0 indicates antagonism. Error bars represent the SEM. 
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Combination MSC2363318A with paclitaxel also contributed to a statistically 
significant increase in apoptosis rates in SKOV3ip1 and Ishikawa (Figure 21). 
 
Figure 21. In vitro effects of MSC2363318A and paclitaxel in ovarian and uterine 
cancer cell lines on apoptosis. Apoptosis assay of SKOV3ip1 and Ishikawa cells 
treated with cell line specific IC50 doses of MSC2363318A, paclitaxel, and combination 
therapy after 72 hours. Error bars represent the SEM. *, P < 0,05; **, P < 0.01; and ***, 
P < 0.001. 
 
 
RPPA identifies YAP1 as a predictor of in vitro response to MSC2363318A 
To identify potential markers of response to MSC2363318A, we used RPPA to 
quantify the protein expression of genes that are modulated after treatment in Igrov1 
and Ovcar5 ovarian cancer cell lines and Hec1B, Ishikawa, KLE, and RL-952 uterine 
cancer cell lines (Figure 22).   
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Figure 22. Differential expression of proteins in the PI3K/AKT/P70S6 signaling 
pathway after MSC2363318A treatment as detected by reverse-phase protein 
array.  Heatmap of proteins whose expression was different before and after treatment 
with MSC2363318A (1 µM) for 18 hours. 
 
 
 
Protein and phosphorylated protein changes were analyzed and uploaded into 
Ingenuity Pathway Analysis (IPA) to perform a network analysis.  We identified the top 
networks that were activated in the ratio of resistant to sensitive cells lines (Table 4).   
 
Table 4.  Top 10 networks in resistant to sensitive ovarian and uterine cancer cell 
lines. 
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Given the robust in vitro and in vivo effects on angiogenesis, we further 
investigated the upregulated pro-angiogenic signaling molecules by a network overlaid 
with the ratio of resistant to sensitive total protein changes (Figure 23).    
 
Figure 23.  Upregulated pro-angiogenic singaling molecules by a network 
overlaid with the ratio of resistant to sensitive total protein change using 
Ingenuity Pathway Analysis. 
 
 
 
 
48 
After a further analysis of only resistant cell lines with and without 
MSC2363318A treatment, we observed an increase in total YAP1 (Figure 24A) 
whereas in the ratio of treated to untreated sensitive cell lines, there was 
downregulation of YAP1 (Figure 24B).  
 
Figure 24.  Differential expression of  angiogenic proteins in the PI3K/AKT/P70S6 
signaling pathway after MSC2363318A treatment as detected by reverse-phase 
protein array.  (A) Pro-angiogenic signaling molecules by a network overlaid with the 
ratio of treated to untreated total protein changes in resistant and (B) sensitive cell lines 
using Ingenuity Pathway Analysis. 
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We plotted the logarithmic ratio values for YAP1 and pYAP1 from the cells lines 
using the RPPA data of the treated over untreated ratio (Figure 25).  Total YAP1 was 
more highly expressed in resistant cell lines.   
 
Figure 25. Logarithmic ratio values for YAP1 and pYAP1 in cancer cell 
lines.  Resistant cell lines were classified by an IC50 ≥ 5 µM. Error bars represent the 
SEM. 
 
We validated our findings from the RPPA by western blot analysis (Figure 26).   
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Figure 26.  Western blot validation using samples submitted for RPPA. 
 
 
YAP1 expression was evaluated in a panel of ovarian (Figure 27A) and uterine 
(Figure 27B) cancer cell lines and a Spearman’s correlation was performed (R=0.675, 
p=0.0015), suggesting that more resistant cell lines have higher YAP1 expression and 
vice versa (Figure 27C).  YAP1 expression was also evaluated by western blot (Figure 
27D), and there was no association between YAP1 protein expression and IC50 
(Figure 27E).  
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Figure 27.  Correlation between YAP1 and MSC2363318A IC50 in ovarian and 
uterine cancer cell lines. (A) Relative expression of YAP1 in uterine (normalized to 
post-menopausal endometrial scrapings) and (B) ovarian cancer cell lines (normalized 
to HIO-180). Quantification was done using the qRT-PCR method. (C) Pearson 
correlation between YAP1 expression and cell line specific IC50 for MSC2363318A. (D) 
YAP1 expression in a panel of ovarian and uterine cancer cell lines.  (E) Spearman’s 
correlation was performed between YAP1 protein expression and MSC2363318A 
IC50.  Error bars represent the SEM. 
 
To address the role of YAP1 overexpression and resistance to MSC2363318A, 
we transfected Ovca432, Igrov1, and Hec1b cells with YAP1 or empty vector and 
characterized them by western blot (Figure 28A).  There were minimal differences in 
apoptotic rates after treatment with MSC2363318A in the cell lines with empty vector or 
YAP1 (Figure 28B). 
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Figure 28.  Characterization of YAP1 overexpressing clones and effects on 
apoptosis after MSC2363318A treatment. (A) Western blot of YAP1 expression in 
transfected cell lines. (B) Cell viability with Ovca432-plx versus Ovca432-YAP1, Igrov1-
plx versus Igrov1-YAP1, and Hec1b-plx versus Hec1b-YAP1 after concentrations of 
MSC2363318A between 0 and 50 µM were added for 96 hours.  Error bars represent 
the SEM. *, P < 0,05; **, P < 0.01; ***, P < 0.001; and ****, P < 0.0001.  
 
 
 
 
Anti-angiogenic effects of MSC2363318A and bevacizumab 
  To address whether MSC2363318A affects endothelial cells in vitro, we 
assessed endothelial cell tube formation. Treatment of sensitive RF-24 endothelial cells 
with MSC2363318A resulted in a 67.2% (p<0.0001) decrease in the number of nodes 
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formed relative to the control group (Figure 29).  Combination MSC23663318A and 
bevacizumab resulted in an 82.8% reduction (p<0.0001) relative to control.   
 
Figure 29.   In vitro effects of MSC2363318A in combination with anti-angiogenic 
therapy in a sensitive endothelial cell line.  Representative pictures of endothelial 
vessel formation of sensitive and bevacizumab-resistant RF-24 cells and quantification 
of the number of number of nodes (points at which where three or more elongated cells 
meet) formed on the gel matrix after prior treatment with 0.5 µg of bevacizumab, 
MSC2363318A with the cell line specific IC20, or combination therapy.  n = 3 wells per 
group and mean number of nodes is quantified from five pictures per well. Error bars 
represent the SEM. ****, P < 0.0001 as determined by the Student t test.  
 
 
 
Clinically, patients develop resistance to anti-angiogenic therapies, so we 
established a bevacizumab resistant RF-24 clone (Figure 30A) to evaluate the 
effectiveness of MSC2363318A in the resistant setting. Cellular viability was assessed 
for the sensitive and resistant RF-24 cell lines (Figure 30B) and the sensitive line had a 
statistically significant lower IC50 (p<0.001).  Endothelial cell tube formation was 
assessed in the resistant RF-24 cell line after treatment with MSC2363318A alone and 
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in combination with bevacizumab, and there were resultant decreases in the nodes 
formed in the groups treated with MSC2363318A (Figure 30C).   
 
Figure 30.   In vitro effects of MSC2363318A in combination with anti-angiogenic 
therapy in a resistant endothelial cell line.  (A) Viability of sensitive and 
bevacizumab-resistant RF-24 cells after treatment with bevacizumab at 0, 0.125, 0.25, 
0.5, and 1 µg for 96 hours and (B) MSC2363318A between 0 to 50 µM ± 0.5 mg of 
bevacizumab for 96 hours and mean inhibitory concentration (IC50). (C) 
Representative pictures of endothelial vessel formation of bevacizumab-resistant RF-
24 cells and quantification of the number of number of nodes (points at which where 
three or more elongated cells meet) formed on the gel matrix after prior treatment with 
0.5 mg of bevacizumab, MSC2363318A with the cell line specific IC20, or combination 
therapy.  n = 3 wells per group and mean number of nodes is quantified from five 
pictures per well. Images were taken at 100× magnification. Error bars represent the 
SEM. **, P < 0.01; and ***, P < 0.001 as determined by the Student t test.  
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We observed a significant reduction in percentage EdU incorporation in both the 
sensitive and resistant RF-24 cell lines treated with combination MSC2363318A and 
bevacizumab suggesting a potentially additive benefit in both the sensitive and 
resistant setting (Figure 31A).  Treatment of resistant and sensitive RF24 cells with 1 
µM of MSC2363318A led to a reduction of p-S6 ribosomal protein and increase in 
pAKT473 (Figure 31B). 
 
Figure 31. Effect of treatment with MSC2363318A in combination with 
bevacizumab on proliferation and downstream. (A) Percentage of EdU 
incorporation in sensitive and bevacizumab-resistant RF-24 cells after treatment 
without (-) and with (+) bevacizumab and cell line specific IC50 concentrations of 
MSC2363318A after 72 hours. (B) Western blot of downstream markers after sensitive 
and resistant RF-24 cells were treated with 1 µM MSC2363318A for 24 hours. 
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The addition of MSC2363318A and bevacizumab to resistant RF-24 cells led to 
a 78.5% reduction in the MSC2363318A IC50, which became less than the 
MSC2363318A IC50 of sensitive RF-24 cells (Figure 32).  
 
Figure 32.  Effect on MSC2363318A IC50 in resistant and sensitive RF-24 cells 
with and without bevacizumab. Viability of sensitive and bevacizumab-resistant RF-
24 cells after treatment with MSC2363318A between 0 to 50 µM ± 0.5 mg of 
bevacizumab for 96 hours and mean inhibitory concentration (IC50). Data represent 
average of triplicate measurements and error bars represent the SEM. ****, P < 0.0001 
as determined by the Student t test.  
 
 
 
Given the effects of MSC2363318A on angiogenesis in vitro, we evaluated the 
effects on angiogenesis in vivo by calculating the microvessel density (MVD) of tumors 
harvested at the conclusion of the therapy experiments. In the SKOV3ip1 tumor model, 
treatment with MSC2363318A alone or in combination with paclitaxel decreased MVD 
by 61.8% (p<0.05) and 63.1% (p<0.01), respectively (Figure 33A). Similar effects of 
CD31 were observed in the Hec1a orthotopic murine model with significant reductions 
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in MSC2363318A (36%, p<0.05) and combination MSC2363318A groups (32.4%, 
p<0.05) (Figure 33B).   
 
Figure 33. In vivo effects of MSC2363318A on angiogenesis in combination with 
paclitaxel. Immunohistochemistry was performed to evaluate the effects of 
MSC23633318A, paclitaxel, or combination therapy on cancer cell angiogenesis 
(CD31). Representative sections (final magnification, ×20) are shown for the four 
treatment groups with the average number of CD31-positive vessels per field in mice 
inoculated with SKOV3ip1 (A) and Hec1a (B). Error bars represent the SEM. *, P < 
0,05; **, P < 0.01. 
 
 
We further investigated the effects of MSC2363318A in combination with an 
anti-angiogenic therapy, bevacizumab. Substantial reductions in tumor weight were 
observed in all groups but most profound (96% reduction compared to control, 
p<0.0001) in the group treated with MSC2363318A and bevacizumab (Figure 
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34A).  Less distant metastases were observed in monotherapy and combination 
therapy groups (Figure 34B-C).  A significant reduction in mouse weight was present in 
the combination bevacizumab and MSC2363318A group (Figure 34D).  Tumor nodules 
were significantly decreased observed in all treatment groups Figure 34E).   
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Figure 34.  In vivo effects of MSC2363318A in combination with anti-angiogenic 
therapy in an ovarian orthotopic model. Mice inoculated with (A-C) HeyA8 ovarian 
cancer cells received vehicle (control), MSC2363318A (25 mg/kg oral daily), 
bevacizumab (6.25 mg/kg intraperitoneally twice weekly), or a combination of 
MSC2363318A and bevacizumab beginning ten days after inoculation. Tumor size and 
sites of metastases were recorded and representative pictures are shown.  (D-E) 
Mouse weights and number of metastatic nodules from mice inoculated with HeyA8 
received vehicle, MSC2363318A, bevacizumab, or a combination of MSC2363318A 
and bevacizumab beginning ten days after inoculation. Error bars represent the SEM. *, 
P < 0,05; **, P < 0.01; ***, P < 0.001; and ****, P < 0.0001.  
 
In the HeyA8 tumors, there was a 57.7% (p<0.05) and 59.5% (p <0.01) 
reduction in MVD in the MSC2363318A monotherapy and combination therapy groups, 
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respectively (Figure 35).  Similar to the other orthotopic models, treatment with 
MSC2363318A and bevacizumab resulted in decreased cellular proliferation and 
increased apoptosis (Figure 35).  
 
Figure 35. Effects of MSC2363318A and bevacizumab on angiogenesis, 
proliferation and apoptosis in an ovarian orthotopic model. Immunohistochemistry 
was performed to evaluate the effects of MSC23633318A, bevacizumab, or 
combination therapy on MVD (CD31), proliferation (Ki67), and apoptosis (cleaved 
caspase-3 [CC3]) staining. Representative sections (final magnification, ×20) are 
shown for the four treatment groups. Mean Ki67-positive cells mean cleaved caspace-3 
cells, and average number of MVD are shown in the adjoining graphs.  Five fields per 
slide and at least five slides per treatment group were examined and compared using 
the Student t-test. Error bars represent the SEM. *, P < 0,05; **, P < 0.01; ***, P < 
0.001; and ****, P < 0.0001.  
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Discussion 
The key findings in this manuscript are that dual inhibition of AKT and P70S6K 
by the novel inhibitor, MSC2363318A, has therapeutic efficacy in multiple preclinical 
models by enhancing cellular apoptosis, inhibiting proliferation, and reducing the 
formation of vasculature.  Synergy was observed in both cancer types with the 
combination of MSC2363318A and paclitaxel.  Addition of MSC2363318A to anti-
angiogenic therapy potentiated the effects of bevacizumab and restored sensitivity in 
the resistant setting.  Finally, we identified YAP1 as a predictor of sensitivity to 
inhibition with MSC2363318A.  
The frequent activation of the PI3K/AKT pathway in malignancies makes it a 
desirable target for therapeutic intervention.  The first drugs developed to target this 
pathway and approved for treatment included the rapamycin analogs, which included 
temsirolimus and everolimus.  Mechanistically, the drugs allosterically inhibit mTORC1.  
Other broad classes of inhibitors that have since been developed: (1) ATP competitive 
dual inhibitors of class I PI3K and mTOR, (2) PI3K inhibitors that inhibit all four class I 
PI3K isoforms (α, β, δ, and γ); (3) specific PI3K isoform inhibitors; (4) ATP competitive 
inhibitors of mTOR; and (5) AKT allosteric and catalytic inhibitors [64].   
The first PI3K inhibitors, including Wortmannin and LY294002, could bind all 
class I PI3Ks and lead to pan-inhibition of this pathway. Due to their poor selectivity 
and pharmacokinetic properties, their therapeutic potential remained limited [27]. 
Recent pan-class I inhibitors include GDC-0941, BKM120, and PX866.  All of these are 
being tested in ongoing trials for solid and hematologic malignancies including breast, 
colorectal and squamous cell carcinomas, melanoma, and lymphomas [27].  Second 
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generation PI3K inhibitors targeted specific PI3K isoforms and are being evaluated in 
preclinical and clinical studies. GDC-0032 is specific for PI3Kα, which may spare 
patients from commonly experienced metabolic abnormalities [65,66]. GSK2636771, 
specific for the PI3Kβ isoform, has been studied in a variety of solid malignancies, 
especially those that lack PTEN [67].  IPI-145 has been tested in several hematologic 
malignancies because it preferentially targets PI3Kδ and PI3Kγ, which are the two 
isoforms that are preferentially expressed on leukocytes [68]. CAL-101, which is PI3Kδ 
specific, has been tested in acute myelogenous leukemia, chronic lymphocytic 
lymphoma, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and multiple myeloma 
[69]. 
The third generation included dual PI3K/mTOR inhibitors, which target PI3K 
class I isoforms, mTORC1, and mTORC2, which led to greater inhibition of this entire 
pathway (19). For example, NVP-BEZ235, has been tested in renal cell and breast 
cancers.  This drug inhibits both ATM and DNA-PKcs and is considered to also be a 
radiosensitizer.  Its lack of bioavailability has prevented further development [70,71].     
Three isoforms of AKT possess biologic relevance in cancer pathogenesis and 
phosphorylation activates multiple downstream signaling cascades including TSC2 
protein, TSC1, mTOR, BAD, and caspase-9 (20).  AKT inhibitors in preclinical and 
clinical development include perifosine, a phospholipid derivative of 
alkylphosphocholine, MK-2206, an allosteric inhibitor of AKT, RX-0201, 20-mer 
antisense oligodeoxynucleotide directed against AKT, Erucylphosphocholine, PBI-
05204, GSK690693, and XL-418 (21).  XL-418, which inhibited both AKT and P70S6K, 
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was tested in a phase I clinical trial in patients with advanced solid tumors.  This study 
was ended due to low drug exposure (NCT00460278).  
Successful targeted therapy depends on identifying biomarkers that can be used 
further during clinical development. This helps to identify which patients are most likely 
to respond while avoiding untoward toxicities in those patients who will not [72]. 
Previous data has identified gain of function mutations in PIK3CA may cause a tumor 
to be more sensitive to PI3K inhibition [67]. Up to 91% of uterine cancers may harbor a 
mutation or alteration in PTEN, which contributes to activation of the PI3K/AKT 
pathway [22]. This may explain why KLE, which is wild type for PTEN and PIK3CA, 
may be the most resistant among the uterine cell lines tested.  Furthermore, Hec1b has 
a mutation in PIK3CA, but not PTEN.  
Despite the large number of inhibitors developed to target to this pathway, none 
of these is able to induce a durable complete remission.  This is largely due to 
resistance that develops and the lack of understanding behind what drives the 
molecular basis of resistance, whether it is acquired or intrinsic. Proposed mechanisms 
of resistance include secondary mutations, crosstalk between other pathways that then 
activate survival mechanisms, and/or amplification of downstream targets within the 
same targeted pathway [73]. Resistance to PI3K/AKT inhibitors under current 
development has been linked to the negative feedback loops.  Within one of these 
loops, inhibition of mTORC1 leads to the upregulation of tyrosine kinase receptors 
(such as platelet derived growth factor receptor [PDGFR] or insulin receptor substrate-1 
[IRS-1]).  This leads to an increase in phosphorylation of AKT at the serine473 residue.  
Within a second loop, inhibitor of mTORC1 leads to further PI3K-Ras activation, which 
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thereby increases the activation of the MAPK pathway [74].  Activation and 
amplification of MYC may also contribute to inherent resistance of therapeutics that 
targets this pathway. This parallel pathway may have increased MYC activation 
through PDK-1 dependent MYC phosphorylation and abrogate the effects of an 
inhibitor of the PI3K/AKT pathway [75].  This feedback inhibition provides the rationale 
for further development of MSC2363318A, which inhibits AKT1, AKT3, and P70S6K.  
Dual inhibition of AKT and further downstream abrogates the negative feedback loop 
activation that earlier inhibitors of this pathway caused.  
One of the most important issues to consider during drug development remains 
drug toxicities, side effects, and potentially “off-target” effects.  The majority of side 
effects related to therapeutics targeting the PI3K/AKT pathway have been mild to 
moderate and able to be managed with supportive, expectant management alone [76]. 
The reported dose limiting side effects from early clinical trials include hyperglycemia, 
gastrointestinal side effects (including nausea, vomiting, diarrhea, and anorexia), 
stomatitis, and maculopapular rash [77].  Some of these side effects can be considered 
“off-target,” however most are related to the primary mechanism of action. For 
example, PI3K inhibitors cause hyperglycemia because this pathway is involved in the 
insulin signaling pathway. Side effects warrant careful attention and may be useful 
during dose escalation studies and further clinical decision making [78].  Dual inhibitors 
of PI3K and mTORC1/2 have been reported to cause a wider variety of off-target 
effects, such as elevated transaminases and fatigue, but their utility has not been 
hampered. During our treatment with MSC2363318A, we observed weight loss in the 
mice receiving treatment, but no behavioral effects or direct side effects were observed.   
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Our preclinical data indicate that MSC2363318A promotes apoptosis, inhibits 
proliferation, and restores sensitivity to bevacizumab resistant tumors in both ovarian 
and uterine cancer. The first phase I trial that is an open-label, non-randomized, dose 
escalation, trial to explore the safety, tolerability, pharmacokinetic, pharmacodynamics, 
and clinical activity of MSC2363318A in patients with advanced malignancies has 
recently opened (NCT01971515).  While the niche of this compound remains 
undetermined, future directions include administration of MSC2363318A as an adjuvant 
therapy in combination with taxane-based therapy after surgical cytoreduction. Other 
alternatives include combining MSC2363318A with bevacizumab or other anti-
angiogenic therapies in patients whose tumors have developed resistance so that 
sensitivity to bevacizumab can be restored.  Finally, the identification of high YAP1 
expression identifies those tumors that are most sensitive to inhibition by 
MSC2363318A.  By identifying the subset of patients whose tumors would be most 
sensitive to dual AKT/P70S6K inhibition, lower treatment doses could be considered, 
overtreatment of patients who would not benefit will be avoided, and untoward toxicities 
in patients who will not respond, would be prevented. 
 
Future directions and translational relevance 
 The challenge of targeted therapies directed toward the PI3K/AKT pathway is 
multifaceted.  With the advent of so many inhibitors, a rational approach should be 
developed to determine in which contexts each inhibitor should be used.  This would 
include clinical and prognostic factors as well as the genomic composition of the 
tumors.   
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With regard to translating my research findings into clinical trials, rational 
combinations should be considered and whether a PI3K/AKT inhibitor should be added 
to standard of care chemotherapy in the adjuvant setting. One way in which this can be 
evaluated is through “window-of-opportunity” trials. In this trial design, women with 
newly diagnosed ovarian cancer (as confirmed by pathologic biopsy), would receive a 
study drug such as MSC2363318A for one to two weeks between the time of biopsy 
and surgical resection.  This allows for physician-scientists to evaluate the targets 
modulated by the study drug after a given period of exposure time and determine if 
additional modifications to clinical development should be considered. Additionally, 
pharmacokinetic assessments can be made on post-resection samples. Alternatively, if 
the woman received neoadjuvant therapy instead of upfront surgical resection, the 
biological agent can be added along with traditional chemotherapy for a longer period 
of time prior to surgery. One of the primary reasons alternative clinical trial designs 
must be considered is that traditional ways of evaluating response through Response 
Evaluation Criteria in Solid Tumors (RECIST) criteria, invalid conclusions may be 
reached about the potential benefit of an investigational agent. Pre-surgical studies 
such as these may further expedite approval of these agents because they shed light 
on the biologic effect of the drug early in the development, rather than waiting for the 
results of Phase II and III studies.  Furthermore, they contribute to the validation of 
markers that will help clinicians identify which patients will best benefit from this type of 
therapy.  Other possibilities include use of inhibitors as a maintenance therapy after 
complete surgical resection and after frontline therapy (e.g., trial designs used in 
GOG218 and ICON7 – details mentioned in Introduction).  In this type of trial design, 
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women would be assigned to receive standard chemotherapy after surgical 
cytoreduction with and without the investigational agent during the therapy and with 
and without the agent after chemotherapy has ended for a pre-specified length of time.  
Due to the activation of the PI3K/AKT pathway in angiogenesis and the resistant 
endothelial studies from this study, consideration could also be given to the addition of 
MSC2363318A to bevacizumab. The work presented here suggests that the addition of 
MSC2363318A to bevacizumab in the resistant setting may resensitize the tumor cells 
to therapy.   
Due to the emergence of resistance to anti-angiogenesis therapy clinically, we 
are currently investigating whether MSC2363318A can overcome such resistance, and 
we are currently studying this in a model of adaptive resistance. This model requires 
intraperitoneal injections of luciferase-labeled cells to allow for confirmation of tumor 
establishment with bioluminescence imaging with randomization to two treatment 
groups:  (1) control and (2) bevacizumab treatment. After three weeks of continuous 
bevacizumab treatment and weekly imaging, mice will be subsequently divided into 
bevacizumab-sensitive and bevacizumab-resistant groups based on tumor growth as 
evidenced by increased bioluminescence intensity in previously stable tumor burden.  
At the emergence of resistance in the previously sensitive group, MSC2363318A is 
added to the bevacizumab treatment.  The combined treatment will continued until mice 
become moribund. We hypothesize that the additional of MSC2363318A at the 
emergence of resistance will halt tumor growth and prolong survival, as compared to 
either control or bevacizumab treatment alone.  
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As a follow-up to this preclinical study, we could identify women whose tumors 
“breakthrough” bevacizumab in the recurrent setting. Women could subsequently be 
randomized to receive continued bevacizumab with the addition of MSC2363318A or 
another standard therapy for recurrent disease by the National Comprehensive Cancer 
Network (NCCN) guidelines.  Using more frequent imaging and markers of clinical 
response, progression free survival and overall survival of these two groups could be 
compared. 
Other important niches to consider would be the effect of MSC2363318A on 
bulky tumors.  This pre-clinical model is also currently being investigated after injection 
of luciferase-labeled uterine cells that were injected into the uterine horn.  After 
established, measurable tumor growth is recorded by IVIS imaging, mice were 
randomized to four different treatment groups:  (1) vehicle; (2) MSC2363318A; (3) 
paclitaxel; and (4) MSC2363318A and paclitaxel.  Weekly quantifications of tumor 
volumes are made and mice are sacrificed with they become moribund. The effect of 
MSC2363318A as a monotherapy and in combination with chemotherapy on survival 
must be further investigated.   
With the ever increasing number of targeted therapies, the addition of 
MSC2363318A with other novel agents should be tested.  This includes poly-ADP 
ribose polymerase (PARP) inhibitors recently approved for recurrent ovarian cancer in 
BRCA mutation carriers. Preclinical work has shown that PI3K inhibition is correlated 
with the loss of homologous recombination repair, which increases DNA damage, and 
could lead to further sensitization of tumor cells by PARP inhibition [79].  An ongoing 
phase I trial combines olaparib, a PARP inhibitor, with a PI3K inhibitor in patients with 
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high grade serous ovarian cancer and triple negative breast cancer [80]. This 
combination has been already investigated in pre-clinical models of triple negative 
breast cancer.  In this study, a pan-class IA PI3K inhibitor (NVP-BKM120) was 
combined with olaparib, which delayed tumor doubling in the combination therapy 
groups [79,81]. While olaparib is currently only approved for women with BRCA 
mutations, the addition of a PI3K/AKT inhibitor such as MSC2363318A could potentially 
make tumor cells without a somatic or germline BRCA mutation sensitive even more 
sensitive to PARP inhibition.  
 
Study limitations 
 Here, we show compelling evidence that MSC2363318A promotes anti-tumoral 
growth and proliferation in pre-clinical models of ovarian and uterine cancer. High 
YAP1 expression is correlated with resistance to apoptosis after treatment with 
MSC2363318A.  The mechanism of how YAP1 contributes to resistance remains 
unknown at this point.  Profiling resistant cells such as SKOV3ip1, Ishikawa, and KLE 
after YAP1 knockdown and performing genomic profiles would give further insight into 
this mechanism.  In cells that were transfected to overexpress YAP1, there was a slight 
protection against cell death, but this slight increase does not account for the protection 
afforded by nontransformed cells that overexpress YAP1.   
 Another limitation to this work is that only ovarian and uterine models were 
investigated.  The PI3K/AKT pathway is one of the most frequently activated signaling 
pathways in cancer, so MSC2363318A may have broader effects on tumor growth in 
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other solid malignancies.  Patient derived xenograft models should be considered in 
future studies.   
 
Implications  
 On the basis and considerations described here, we show that MSC2363318A 
has therapeutic efficacy in multiple ovarian and uterine orthotopic models.  Reductions 
in tumor weight, number of metastatic sites and nodules were observed without dose 
limiting side effects.  This dual AKT1, AKT3, and P70S6K inhibitor inhibits cellular 
proliferation, promotes tumoral apoptosis, and decreases small vessel formation. The 
efficacy observed makes MSC2363318A a novel small molecule therapeutic that is 
worthy of further clinical development in patients in the frontline in combination with 
paclitaxel or in the recurrent setting.  Our RPPA and in vitro validation suggest that 
YAP1 represents a biomarker that may identify those patients whose tumor may be 
most sensitive to this type of dual inhibition.  Further, mechanistic studies are needed 
to better understand the molecular biology between these two pathways.   
 Moreover, given our findings in vivo and the effects of MSC2363318A on 
angiogenesis, we showed that in the resistant setting, the additional of MSC2363318A 
may allow for resensitization to anti-angiogenic agents.  The addition of MSC2363318A 
to patients who have become resistant to bevacizumab may improve survival and 
prolonged, durable responses. 
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Conclusions:  
Our preclinical data demonstrate that MSC2363318A may be therapeutically 
beneficial to ovarian and uterine cancer patients in combination with taxane-based 
therapies or anti-angiogenic therapies in the sensitive and resistant setting.  YAP1 
represents a potential predictive biomarker for predicting sensitivity of the cancer 
response to this treatment. 
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